While biosimilar medicines have offered a great deal of savings for US healthcare, the current system may negatively affect the long-term sustainability of the sector, potentially leading to a decrease in biosimilar developers and monopolization of the market, suggests a new IQVIA report.
According to the report titled “Long-term Market Sustainability for Infused Biosimilars in the US”, biosimilars have been associated with $56bn in savings between 2013 and 2022 and hold the potential for over $180bn in savings between 2023 and 2027